ASH 2021 | Top MPNs news at ASH 2021: pemigatinib, rusfertide, avapritinib and pelabresib
Prithviraj Bose, MD, The University of Texas MD Anderson Cancer, Houston, TX, highlights key news in the myeloproliferative neoplasms (MPNs) space presented at the ASH 2021 annual meeting. Dr Bose first comments on findings from FIGHT-203 (NCT03011372), a Phase II study to evaluate the efficacy and safety of pemigatinib in patients with myeloid/lymphoid neoplasms with FGFR1 rearrangement. Pemigatinib was shown to elicit high rates of durable responses in these patients and thus, may offer a long term-treatment option for patients ineligible for stem cell transplantation. Dr Bose also comments on updated data on rusfertide, a synthetic hepcidin mimetic which continues to show clinically meaningful benefits for polycythemia vera patients. Finally, Dr Bose discusses the Phase I/II MANIFEST (NCT02158858) trial of pelabresib with or without ruxolitinib for patients with myelofibrosis. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
